| Sequential versus standard conditioning in untreated MDS patients with blasts undergoing allogeneic HSCT |
|
Bone Marrow Transplant |
Myelodysplastic Syndromes (MDS) |
| Immunosuppressive therapy versus haploidentical transplantation in adults with acquired severe aplastic anemia |
|
Bone Marrow Transplant |
Aplastic Anemia |
| Palliative Medicine in Myelodysplastic Syndromes: Patients and Caregivers - A Qualitative Study |
|
BMJ Supportive & Palliative Care |
Myelodysplastic Syndromes (MDS) |
| MDS with 5q deletion and rare cKIT positive mastocytosis: a diagnostic and therapeutic challenge |
|
BMJ Case Reports |
Myelodysplastic Syndromes (MDS) |
| Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria |
|
Blood, cells, molecules & diseases |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Severe breakthrough hemolysis during compassionate use of Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: managing an emergency |
|
Blood Transfusion |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Current and emerging strategies for management of myelodysplastic syndromes |
|
Blood reviews |
Myelodysplastic Syndromes (MDS) |
| Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age |
|
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
| Paroxysmal nocturnal hemoglobinuria: Review of the patient experience and treatment landscape |
|
Blood Reviews |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria |
|
Blood Reviews |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
